Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Eva Catala"'
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Autor:
Mi Kwon, Gloria Iacoboni, Juan Luis Reguera, Lucía López Corral, Rafael Hernani Morales, Valentín Ortiz-Maldonado, Manuel Guerreiro, Ana Carolina Caballero, María Luisa Guerra Domínguez, Jose Maria Sanchez Pina, Alberto Mussetti, Juan Manuel Sancho, Mariana Bastos-Oreiro, Eva Catala, Javier Delgado, Hugo Luzardo Henriquez, Jaime Sanz, María Calbacho, Rebeca Bailén, Cecilia Carpio, Jose Maria Ribera, Anna Sureda, Javier Briones, Juan Carlos Hernandez-Boluda, Nuria Martínez Cebrián, Jose Luis Diez Martin, Alejandro Martín, Pere Barba
Publikováno v:
Haematologica, Vol 108, Iss 1 (2022)
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and
Externí odkaz:
https://doaj.org/article/7877186aef5347968a5ec57a48454215
Autor:
Guillermo Villacampa, Ana Pérez, Marc Simó, Sabela Bobillo, Eva Catala, Francesc Bosch, Cecilia Carpio, Pau Abrisqueta, Moraima Jiménez, Pere Barba, Gloria Iacoboni, Cándido Díaz-Lagares, Angela Vidal-Jordana, Ana Marín-Niebla
Publikováno v:
Annals of Hematology. 100:2303-2310
Chimeric antigen receptor (CAR) T-cell therapy provides long-term remissions in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Total metabolic tumor volume (TMTV) assessed by 18F-fluorodeoxyglucose positron emission tomograp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca06867c006fc4951d9d9449f6234909
https://doi.org/10.1007/s00277-021-04560-6
https://doi.org/10.1007/s00277-021-04560-6
Autor:
Pau Abrisqueta, Guillermo Villacampa, Moraima Jiménez, Pere Barba, Ana Pérez, Francesc Bosch, David Valcárcel, Cecilia Carpio, Gloria Iacoboni, María Josep Carreras, Sabela Bobillo, Anna Farriols, Eva Catala, Mireia Olivé, Laura Segura
Publikováno v:
Leukemia & Lymphoma. 62:2288-2291
Chimeric antigen receptor T-cells (CAR-T) have recently emerged as an active therapy for patients with relapse or refractory diffuse large B-cell lymphoma (R/R DLBCL) [1]. Clinical trials using ant...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6aef8ee7483d6deeb8546e8fccfeef1
https://doi.org/10.1080/10428194.2021.1913141
https://doi.org/10.1080/10428194.2021.1913141
Autor:
Ana Perez, Sabela Bobillo, Guillermo Villacampa, Eva Catala, Moraima Jiménez, Pere Barba, Ana Marin-Niebla, Pau Abrisqueta, Angela Vidal-Jordana, Cecilia Carpio, Gloria Iacoboni, David Valcárcel, Francesc Bosch, Cándido Díaz-Lagares, Marc Simó
Publikováno v:
Blood. 136:27-29
Introduction Chimeric antigen receptor (CAR) T-cell therapy provides long-term remissions in a substantial proportion of patients with large B-cell lymphoma (LBCL) who have relapsed or are refractory (R/R) to chemoimmunotherapy. The identification of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9242564b900538f22c5b9baf7e167cf
https://doi.org/10.1182/blood-2020-141777
https://doi.org/10.1182/blood-2020-141777
Autor:
Moraima Jiménez, Ana Pérez, Francesc Bosch, Pamela Arenas, Eva Catala, Sabela Bobillo, Lucia Martin, Yva Rodriguez, David Valcárcel, Alba Cabirta, Angel Serna
Publikováno v:
Blood. 136:14-16
INTRODUCTION For more than two decades, the treatment of aTTPconsisted of therapeutic plasma exchange (TPE) and immunosuppressive agents. The addition of caplacizumab, a nano-antibody that binds to the A1 domain of the von Willebrand factor, inhibiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d00891cfd98191d6d46081cec0ef202a
https://doi.org/10.1182/blood-2020-142987
https://doi.org/10.1182/blood-2020-142987
Autor:
Reyes Maria Martin Rojas, José Luis Díez-Martín, Annalisa Paviglianiti, Pere Barba, Mariana Bastos-Oreiro, María Calbacho, Javier Delgado Serrano, José Morales Sánchez, Manuel Guerreiro, Juan Carlos Hernandez Boluda, Eva Catala, Alejandro Martin Garcia-Sancho, Valentín Ortiz-Maldonado, Javier Briones, Rafael Hernani, Jaime Sanz, Lucía López Corral, Rebeca Bailén, Ana Carolina Caballero, Gillen Oarbeascoa, Juan Reguera, Alberto Mussetti, Gloria Iacoboni, Mi Kwon, Juan-Manuel Sancho
Publikováno v:
Blood. 138:1742-1742
Introduction: Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are the two autologous anti-CD19 chimeric antigen receptors T cells commercially approved in Europe for relapsed/refractory (R/R) DLBCL. We performed a retrospective stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd49821a4e0aa67ae8869d12dff54f58
https://doi.org/10.1182/blood-2021-147369
https://doi.org/10.1182/blood-2021-147369
Autor:
Eva Catala, Lucia Martin, Macarena Izuzquiza, Pau Abrisqueta, Rodrigo Dienstmann, David Valcárcel, Isabel Ruiz-Camps, Fiorella Ruiz-Pace, Yva Rodriguez, Moraima Jiménez, Sabela Bobillo, Olga Salamero, Ana Pérez, Alba Cabirta, Cecilia Carpio, Francesc Bosch, Angel Serna
Publikováno v:
Blood
INTRODUCTION: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic raises many questions about the management of patients with significant comorbidities. Hematologic patients are usually fragile due to an important immunosuppress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e41b798a6205171bfeec2ff959f1555
https://doi.org/10.1182/blood-2020-141991
https://doi.org/10.1182/blood-2020-141991
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.